Cendakimab

From Wikipedia, the free encyclopedia

Other namesRPC4046; ABT 308; CC-93538
ATC code
  • None
Cendakimab
Monoclonal antibody
Type?
TargetInterleukin 13
Clinical data
Other namesRPC4046; ABT 308; CC-93538
ATC code
  • None
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
KEGG

Cendakimab (RPC4046; ABT 308; CC-93538) is a monoclonal antibody against interleukin 13. It is developed by Bristol Myers Squibb[1] for eosinophilic esophagitis and atopic dermatitis.[2][3][4][5]

Related Articles

Wikiwand AI